/DISREGARD RELEASE: Antengene Corporation Limited/

28.07.25 05:52 Uhr

We are advised by Antengene Corporation Limited that journalists and other readers should disregard the news release, Antengene Announces XPOVIO® Approved in China for the Second-Line Treatment of Multiple Myeloma, Marking the Third Approved Indication of the Drug, issued 28-Jul-2025 over PR Newswire.

SOURCE Antengene Corporation Limited